Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(23 sites)
United States
UCSF Comprehensive Cancer Center, San Francisco, California University of California Los Angeles - Cancer Care - Santa Monica (UCLA), Santa Monica, California Norton Cancer Institute, Louisville, Kentucky START Midwest, Grand Rapids, Michigan Hackensack University Medical Center, Hackensack, New Jersey MD Anderson Cancer Center, Houston, Texas START San Antonio, San Antonio, Texas Ireland
START - Dublin Mater Misericordiae University Hospital (MMUH), Dublin Japan
National Cancer Center East, Kashiwa Kyoto University Hospital, Kyoto Kansai Medical University Hospital, Osaka National Cancer Center Hospital, Tokyo Portugal
START Lisboa a - Unidade de Ensaios ClÃnicos - Hospital de Santa Maria, Lisbon Spain
Hospital Universitario Vall d'Hebron, Barcelona START Barcelona, Barcelona START - Rioja Hospital Universitario San Pedro, Logroño START Madrid Hospital Universitario Fundacion Jimenez Diaz, Madrid START Madrid Hospital Universitario HM Sanchinarro - CIOCC, Madrid NEXT Oncology Madrid, Madrid Hospital Universitario Virgen de la Victoria, Málaga Clinica Universidad de Navarra, Pamplona Taiwan
National Taiwan University Hospital, Taipei Taipei Veterans General Hospital, Taipei